number of weight loss drug prescriptions q3 2024 semaglutide tirzepatide New weight-loss drugs set to shake up pharma in 2026. Plus, semaglutide's patent expiry across major emerging markets, including India, Brazil and China, is expected to open the field to generic manufacturers GLP-1 prescription trends through June

Ravi Sankar Erukulapati Indian Institute of Technology, Madras IIT Madras Research Park (IITMRP) National Institute of Technology, Tiruchirappalli National Health Authority (NHA) ISRO - Indian Space Research Organization Confederation of Indian Industry Star Health and Allied Insurance Co

FDA Commissioner Marty Makary stated that the agency was paying close attention to misleading claims "across all media platforms." For consumers, the most important compliance signal to look for in any compounded GLP-1 program is whether the company accurately describes what its medications are and are not

How does Ipamorelin differ from Sermorelin and Tesamorelin

To address this, we conducted subgroup analyses stratified by diabetes status and reported differential responses in HbA1c reduction and weight loss

143 FerranteK